Jeffrey Grand is a Partner at Seeger Weiss who focuses his practice on complex individual and class action litigation involving pharmaceutical injury, medical devices, and dangerous consumer products. Having been with Seeger Weiss since 2004, Jeff is one of the firm’s most tenured attorneys. Jeff has been involved in every aspect of these complex cases—from pre-litigation strategy and discovery negotiations to document productions, depositions, and expert development, through to trial and resolution.
Jeff serves as the Discovery Chair and on the Plaintiffs’ Steering Committee in the C.R. Bard Hernia Mesh Litigation and was a member of the trial teams in all three of the bellwether trials, securing plaintiff verdicts in two of the trials. He also served as co-chair of the eDiscovery and Depository Committees in the Xarelto (Rivaroxaban) Product Liability Litigation, which reached a $775 million settlement on behalf of more than 25,000 plaintiffs. He also played a key role in the Proton-Pump Inhibitor (PPI) Products Liability Litigation, supporting Chris Seeger in settling $590.4 million for plaintiffs who alleged popular PPI medications caused kidney damage. Jeff served as a member of the Plaintiffs’ Steering Committee, overseeing seven federal multidistrict litigations involving transvaginal mesh products. In this capacity, he made significant contributions to case discovery and was a member of multiple trial teams in both state and federal courts. Notably, Jeff was a member of the trial team in Gross v. Gynecare Inc., a transvaginal mesh case filed in New Jersey state court, which resulted in a plaintiffs’ verdict of over $11 million.
Previously, Jeff was a member of trial teams in both federal and state courts overseeing the Vioxx litigation and helped obtain a $47.5 million verdict for Vioxx-related cardiovascular injury in Humeston v. Merck, Inc. (admitted pro hac vice). Additionally, Jeff played a key role in discovery and served on the trial teams in the Chinese Manufactured Drywall Products Liability Litigation.
More recently, he has contributed to the firm’s work on emerging issues, including the Phenylephrine Decongestants Marketing and Sales Practices Litigation, where he is the co-chair of discovery, the Invokana Products Liability Litigation where he also served as the co-chair of discovery, and the Social Media Addiction Products Liability Litigation.
Today, Jeff oversees critical administrative functions at Seeger Weiss, including case intake, client management, and settlement processing. Under his leadership, the firm has implemented advanced technological systems that enhance its ability to effectively represent hundreds of thousands of clients while maintaining personalized service.
Prior results do not guarantee or predict a similar outcome in any future matter.
